A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Clinical Cancer Research

• Publication date

  2003-10-15

• Fields of study

  Medicine

• Identifiers
  PMID 14581346
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.

  2003cited by this paper
• A randomized trial of aspirin to prevent colorectal adenomas.

  2003cited by this paper
• COX selectivity and animal models for colon cancer.

  2002cited by this paper
• Mouse by Rofecoxib , a Specific Cyclooxygenase-2 Inhibitor 716 ∆ Apc Chemoprevention of Intestinal Polyposis in the Updated Version

  2001cited by this paper
• The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.

  2000cited by this paper
• Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group.

  2000cited by this paper
• Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

  2000influential reference
• The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.

  2000cited by this paper
• Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

  1999cited by this paper
• Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

  1999cited by this paper
• Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

  1999cited by this paper
• Cyclooxygenase-2 inhibitors in tumorigenesis (Part II).

  1998cited by this paper
• Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).

  1996cited by this paper
• Suppression of Intestinal Polyposis in ApcΔ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2)

  1996cited by this paper
• Aspirin Use and the Risk for Colorectal Cancer and Adenoma in Male Health Professionals

  1994cited by this paper
• Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis

  1993cited by this paper
• Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.

  1993cited by this paper
• Identification and characterization of the familial adenomatous polyposis coli gene

  1991cited by this paper
• Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients.

  1991cited by this paper
• A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer.

  1991cited by this paper
• Identification of FAP locus genes from chromosome 5q21.

  1991cited by this paper
• Sulindac causes regression of rectal polyps in familial adenomatous polyposis.

  1991cited by this paper
• Aspirin use and reduced risk of fatal colon cancer.

  1991cited by this paper
• Familial adenomatous polyposis: the large bowel.

  1990cited by this paper
• Sulindac for polyposis of the colon.

  1989cited by this paper
• Sulindac for polyposis of the colon

  1983influential reference
• Familial polyposis coli.

  1975cited by this paper

• Safety and efficacy of chemoprevention for familial adenomatous polyposis: a systematic review and meta-analysis

  2026cites this paper
• Familial adenomatous polyposis: non-surgical management of large bowel disease: endoscopic and chemoprevention strategies

  2025cites this paper
• Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2024 for the clinical practice of hereditary colorectal cancer

  2025cites this paper
• Targeting cyclooxygenase-2 for chemoprevention of inflammation-associated intestinal carcinogenesis: An update.

  2024cites this paper
• Which Drugs are More Effective in Preventing Familial Adenomatous Polyposis Progression Based on Network Meta-Analysis?

  2024cites this paper
• Laparoscopic Restorative Total Proctocolectomy with Ileal Pouch-Anal Anastomosis for Familial Adenomatous Polyposis and Ulcerative Colitis

  2023cites this paper
• Chemoprevention in Inherited Colorectal Cancer Syndromes

  2023cites this paper
• Nonsteroidal Anti-inflammatory Drugs for Chemoprevention in Patients With Familial Adenomatous Polyposis: A Systematic Review and Meta-Analysis

  2023cites this paper
• Chemoprevention in hereditary digestive neoplasia: A comprehensive review

  2023cites this paper
• Colorectal Cancer Chemoprevention: A Dream Coming True?

  2023cites this paper
• The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Inherited Adenomatous Polyposis Syndromes.

  2023cites this paper
• Chemoprevention Considerations in Patients with Hereditary Colorectal Cancer Syndromes.

  2022cites this paper
• Chinese consensus on prevention of colorectal neoplasia (2021, Shanghai)

  2022cites this paper
• Long-term chemoprevention in patients with adenomatous polyposis coli: an observational study

  2022cites this paper
• Pathways of Colorectal Carcinogenesis.

  2020cites this paper
• Chemoprevention of Colorectal Cancer.

  2020cites this paper
• Updates in Chemoprevention Research for Hereditary Gastrointestinal and Polyposis Syndromes

  2020cites this paper
• Familial Adenomatous Polyposis: Prophylactic Management of the Colon and Rectum

  2020cites this paper
• Early-onset colorectal cancer: initial clues and current views

  2020cites this paper
• Gastrointestinal Cancer Prevention: Diet, Lifestyle, and Therapeutic Prevention

  2019cites this paper
• Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version)

  2018cites this paper
• Differences in risk factor–colorectal adenoma associations according to non-steroidal anti-inflammatory drug use

  2018cites this paper
• Omega-3 fatty acids, membrane remodeling and cancer prevention.

  2018cites this paper
• Are Colon and Rectal Cancer Two Different Tumor Entities? A Proposal to Abandon the Term Colorectal Cancer

  2018cites this paper
• COLON AND RECTAL CANCER ARE DIFFERENT TUMOR ENTITIES ACCORDING TO EPIDEMIOLOGY, CARCINOGENESIS, MOLECULAR- AND TUMOR BIOLOGY, PRIMARY AND SECONDARY PREVENTION: PRECLINICAL EVIDENCE

  2018cites this paper
• A suppresses intestinal tumor development in Apc mice

  2018cites this paper
• Alternative treatments for prophylaxis of colorectal cancer in familial adenomatous polyposis

  2018cites this paper
• A novel bioactive derivative of eicosapentaenoic acid (EPA) suppresses intestinal tumor development in Apc&Dgr;14/+ mice

  2018cites this paper
• РАЗЛИЧИЕ РАКА ТОЛСТОЙ И ПРЯМОЙ КИШКИ С ТОЧКИ ЗРЕНИЯ ЭПИДЕМИОЛОГИИ, КАНЦЕРОГЕНЕЗА, МОЛЕКУЛЯРНОЙ БИОЛОГИИ, ПЕРВИЧНОЙ И ВТОРИЧНОЙ ПРОФИЛАКТИКИ: ДОКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ

  2018cites this paper
• Chemoprevention in hereditary colorectal cancer syndromes

  2018cites this paper
• The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Inherited Polyposis Syndromes.

  2017cites this paper
• LA QUIMIOPREVENCIÓN PARA PACIENTES CON MUTACIONES HEREDITARIAS DE PREDISPOSICIÓN AL CÁNCER

  2017cites this paper
• Assessing barriers to a rational chemoprevention trial design in young patients with familial adenomatous polyposis

  2017cites this paper
• Differential expression of tumor necrosis factor α, interleukin 1β, nuclear factor κB in nasal mucosa among chronic rhinosinusitis patients with and without polyps

  2017cites this paper
• Randomized Controlled Trials in Hereditary Cancer Syndromes.

  2017cites this paper
• Chemoprevention of hereditary colon cancers: time for new strategies

  2016cites this paper
• Celecoxib induces apoptosis but up-regulates VEGF via endoplasmic reticulum stress in human colorectal cancer in vitro and in vivo

  2016cites this paper
• Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial.

  2016cites this paper
• A Way Forward for Cancer Chemoprevention: Think Local

  2016influential citation
• Aspirin and the Prevention of Colorectal Cancer

  2016cites this paper
• The Role of Aspirin, Vitamin D, Exercise, Diet, Statins, and Metformin in the Prevention and Treatment of Colorectal Cancer

  2015cites this paper
• Adiponectin and selenium rich diet can act as a complimentary medicine in the treatment of intestinal and chronic inflammation induced colon cancer

  2015cites this paper
• Colon Polyps and Pathologic Features

  2015cites this paper
• Cysteinyl leukotriene 1 receptor influences intestinal polyp incidence in a gender-specific manner in the ApcMin/+ mouse model.

  2015cites this paper
• Malignant tumors of the colon

  2015cites this paper
• Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan.

  2015cites this paper
• Hereditary Colorectal Cancer and Polyposis Syndromes

  2015cites this paper
• Chemoprevention trials of GI cancers in Asia.

  2015cites this paper
• The efficacy and safety of non‐steroidal anti‐inflammatory drugs in preventing the recurrence of colorectal adenoma: a meta‐analysis and systematic review of randomized trials

  2015cites this paper
• APhase IbStudyof theEffectsofBlackRaspberriesonRectal Polyps in Patients with Familial Adenomatous Polyposis

  2014cites this paper
• Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome.

  2014cites this paper
• Chemoprevention of Colorectal Cancer by Anti‐Inflammatory Agents

  2014cites this paper
• The role of CysLT1R in mouse models of colorectal cancer

  2014cites this paper
• Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: A phase II TCOG study

  2014cites this paper
• A Phase Ib Study of the Effects of Black Raspberries on Rectal Polyps in Patients with Familial Adenomatous Polyposis

  2014cites this paper
• APhaseIbStudyoftheEffectsofBlackRaspberriesonRectal Polyps in Patients with Familial Adenomatous Polyposis

  2014cites this paper
• Targeted Cox2 gene deletion in intestinal epithelial cells decreases tumorigenesis in female, but not male, ApcMin/+ mice

  2014cites this paper
• Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial

  2013cites this paper
• Discovery and Characterization of Novel Inhibitors of the Prostaglandin E2 Pathway

  2013cites this paper
• Cyclo-oxygenase-2 inhibitors for chemoprevention of nonmelanoma skin cancer: is there a role for these agents?

  2013cites this paper
• Screening and Identification of Salicin Compound from Desmodium gangeticum and its In vivo Anticancer Activity and Docking Studies with Cyclooxygenase (COX) Proteins from Mus musculus

  2013cites this paper
• Chemoprevention of cancers in gastrointestinal tract with cyclooxygenase 2 inhibitors.

  2013cites this paper
• Preclinical Predictors of Anticancer Drug Efficacy: Critical Assessment with Emphasis on Whether Nanomolar Potency Should Be Required of Candidate Agents

  2012cites this paper
• Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer

  2012cites this paper
• Innate Immune Regulation and Cancer Immunotherapy

  2012cites this paper
• [Aspirin in the primary prevention of colorectal cancer].

  2012cites this paper
• Immunotherapy of Cancer

  2012cites this paper
• Aspirin as a chemoprevention agent for colorectal cancer.

  2012cites this paper
• Colorectal Cancer Chemoprevention: Is This the Future of Colorectal Cancer Prevention?

  2012cites this paper
• La aspirina en la prevención primaria del cáncer colorrectal

  2012cites this paper
• COX-2 as a molecular target of colon cancer chemoprevention: Promise and reality

  2012cites this paper
• Eryngium foetidum suppresses inflammatory mediators produced by macrophages.

  2012cites this paper
• Chemoprevention in patients with genetic risk of colorectal cancers.

  2012cites this paper
• Public Health Genomics: Exploiting SNP-NSAID interactions to prevent colorectal cancer

  2011cites this paper
• Familial adenomatous polyposis: clinical presentation, detection and surveillance.

  2011cites this paper
• Clinical trials update: Tertiary prevention of colorectal cancer

  2011cites this paper
• Chemoprevention in familial adenomatous polyposis.

  2011cites this paper
• Rofecoxib does not appear to increase the risk of venous thromboembolism: a systematic review of the literature.

  2011influential citation
• Cyclooxygenase-2 Signaling in Squamous Cell Carcinomas

  2011cites this paper
• INFLAMMATORY MECHANISMS OF CHEMOKINE RECEPTOR 7 EXPRESSION IN METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

  2011cites this paper
• How do cyclin D1, EGFR, and COX-2 attribute to colorectal carcinoma prognosis? An immunohistochemical study on tissue microarray

  2011cites this paper
• Chemoprevention of colorectal cancer: systematic review and economic evaluation.

  2010cites this paper
• Non-Steroidal Anti-Inflammatory Drugs in the Carcinogenesis of the Gastrointestinal Tract

  2010cites this paper
• Características de los pacientes con poliposis adenomatosa familiar en España. Resultados iniciales del Registro Español de Poliposis Adenomatosa Familiar

  2010cites this paper
• [Characteristics of patients with familial adenomatous polyposis in Spain. First results of the Spanish Registry of Familial Adenomatous Polyposis].

  2010cites this paper
• The Safety and Efficacy of Celecoxib in Children With Familial Adenomatous Polyposis

  2010cites this paper
• Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis

  2010cites this paper
• Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells

  2010cites this paper
• Pre Clinical and Clinical Studies of the Effects of Resveratrol, a Phytochemical With Potential Chemopreventive Efficacy

  2010cites this paper
• Strategies for colon cancer prevention

  2010cites this paper
• The surgical management of oral and maxillofacial manifestations of Gardner syndrome.

  2010cites this paper
• Mono-, di-, and triaryl substituted tetrahydropyrans as cyclooxygenase-2 and tumor growth inhibitors. Synthesis and biological evaluation.

  2010cites this paper
• RNAi-Based Strategies for Cyclooxygenase-2 Inhibition in Cancer

  2010cites this paper
• Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor

  2010cites this paper
• 21 Lipids in Neural Tumors

  2009cites this paper
• Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.

  2009cites this paper
• Lipids in Neural Tumors

  2009cites this paper
• Nonsteroidal Anti-inflammatory Drugs

  2009cites this paper
• Aspirin and NSAIDs for the prevention of colorectal cancer.

  2009cites this paper
• Familial adenomatous polyposis

  2009cites this paper